Expanding Canadian Weight Management
Hims & Hers finalizes Eucalyptus acquisition, boosting Canadian weight management access.
Hims & Hers Health has completed its acquisition of Eucalyptus, the Australian digital health company behind Juniper, Pilot, and Kin, in a deal worth up to $1.15 billion USD, according to Financial Post. The move cements Hims & Hers as a dominant force in Canadian weight management, where nearly two-thirds of adults — about 65.7% — are classified as overweight or living with obesity, per Statistics Canada.
For existing Juniper patients in Canada, care continues without interruption. CEO Andrew Dudum said every step in Canada has been guided by "expanding access to the care Canadians need, when they need it."
A $1.15 Billion Bet Built in Six Months
The deal closed June 2, 2026, but the groundwork moved fast. Hims & Hers entered Canada in December 2025 by acquiring Livewell, a local digital health platform. By February 2026, it had announced the Eucalyptus deal. The acquisition structure includes $240 million in upfront cash, $710 million in guaranteed deferred payments over 18 months, and up to $200 million in performance bonuses through 2029, according to Healthcare Digital.
To fund the expansion, Hims & Hers raised $350 million through a convertible notes offering in May 2026, per National Post. The company also reaffirmed its 2030 targets: $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Eucalyptus brings more than 850,000 customers into that picture, adding to Hims & Hers' existing base of over 2 million subscribers.
Generic Semaglutide Fuels a Canadian Price War
The timing of the acquisition lines up with a major regulatory shift. In April 2026, Health Canada authorized the first generic semaglutide injection in any G7 country — made by Canadian drugmaker Apotex Inc. This gave Hims & Hers a legal, approved alternative to brand-name Ozempic. On May 21, the company launched personalized treatment plans starting at $149 CAD per month, according to Calgary Sun.
The move sparked a full price war. Competitors like Felix Health, Phoenix, and Raven rolled out similar generic programs. Monthly costs in the Canadian weight loss market dropped from $400+ CAD to as low as $124.99 CAD, according to Benefits and Pensions Monitor. Dr. Sandy Van, Hims & Hers Canada's chief medical officer, called the generic approval a "turning point" for the country's healthcare landscape.
Why Canada — Not the US — Became the Growth Target
Hims & Hers faced serious legal pressure in the United States. Novo Nordisk sued the company over its sale of compounded GLP-1 medications — cheaper, unbranded versions mixed by specialty pharmacies. The FDA also tightened scrutiny on compounded drugs in 2025, squeezing one of the company's core revenue streams, according to MedCity News.
Canada offered a cleaner path. It was the first G7 nation to lose patent protection on original GLP-1 drugs like Ozempic, opening the door to Health Canada-approved generics — not the contested compounded versions. That regulatory difference let Hims & Hers shift from playing defense in the US to moving first in Canada. Tim Doyle, former Eucalyptus CEO and now Hims & Hers' Senior VP of International, said the combination allows teams to "deepen what we've built... and bring that experience to many more people."
Wall Street Cautious as Debt Mounts and Rivals Watch
Analysts are split on the deal. Jefferies lowered its price target to $24.50 on June 2, keeping a "Hold" rating over missed early Q1 revenue targets. BofA Securities also cut its target to $25.00, citing concerns about 2026 guidance. Truist Securities was more upbeat, raising its target to $23.00 on the long-term potential of the Canadian weight management market, according to Edmonton Examiner.
Some health experts urge caution beyond the financial numbers. Dr. Sanjeev Sockalingam of Obesity Canada said generic semaglutide "changes the landscape" by cutting costs, but stressed that medication alone is not enough. He called for digital platforms to maintain strong clinical standards alongside the lower prices. Meanwhile, some pharmacists at chains like Shoppers Drug Mart have reportedly been slow to substitute brand-name prescriptions with cheaper generics, according to The Observer.
Sentiment
NeutralPublishers
14
Articles
14
Reach
14
